| Literature DB >> 29635646 |
Mari Inohana1, Ayumi Eguchi1, Misato Nakamura1, Rei Nagahara1, Nobuhiko Onda1, Kota Nakajima1,2, Yukie Saegusa3, Toshinori Yoshida1, Makoto Shibutani1,4.
Abstract
Aluminum (Al) is neurotoxic to adults and also to infants. In this study, we investigated the developmental exposure effect of AlCl3 on postnatal hippocampal neurogenesis. Pregnant mice were administered 0-, 900-, or 1800-ppm AlCl3 via drinking water from gestational day 6 to postnatal day (PND) 21, with their offspring examined on PND 21 and PND 77. On PND 21, GFAP-immunoreactive (+) neural stem cells (NSCs) and p21Cip1/Waf1+ cells were decreased in number in the subgranular zone at 900 and ≥900 ppm, respectively. Pcna transcript level examined at 1800 ppm was decreased in the dentate gyrus. These results suggest induction of compromised cell quiescence that caused impaired self-renewal capacity of NSCs accompanying slowing down of cell cycling, which ultimately resulted in exhaustion of the NSC pool. At 1800 ppm, Reelin+ hilar GABAergic interneurons were also decreased, suggesting a contribution to the NSC reduction. At this dose, TBR2+ or DCX+ progenitor and immature granule cells and PVALB+ interneurons were increased. Moreover, COX-2+ granule cells were increased at ≥900 ppm. These results suggest facilitation of transient progenitor cell proliferation and differentiation during exposure. Moreover, TUNEL+ or Morin-stained granule cells were increased, together with Casp12 transcript upregulation, suggesting induction of Al accumulation-related endoplasmic reticulum stress-mediated granule cell apoptosis. Transcript expression changes on cholinergic and glutamatergic signals and synaptic plasticity suggested contribution to disruptive neurogenesis. The NSC-targeting effects sustained through the adult stage despite no sustained Al-accumulation. These results suggest that developmental AlCl3-exposure irreversibly affects postnatal hippocampal neurogenesis involving multiple functions in mice.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29635646 PMCID: PMC6016705 DOI: 10.1093/toxsci/kfy081
Source DB: PubMed Journal: Toxicol Sci ISSN: 1096-0929 Impact factor: 4.849
Figure 1.Body weight (A), food consumption (B), and water consumption (C) of dams during the exposure period. *p < .05, **p < .01, compared with the 0-ppm controls by Dunnett’s test or Aspin-Welch’s t-test with Bonferroni correction.
Body and Brain Weights of Offspring on PND 21 and PND 77
| AlCl3 in Drinking Water (ppm) | |||
|---|---|---|---|
| 0 (Control) | 900 | 1800 | |
| PND 21 | |||
| Males | |||
| No. of offspring examined | 36 | 30 | 33 |
| Body weight (g) | 17.9 ± 0.9 | 16.9 ± 1.3 | 15.6 ± 0.8 |
| No. of offspring examined | 24 | 20 | 22 |
| Brain weight (g) | 0.45 ± 0.02 | 0.44 ± 0.01 | 0.43 ± 0.01 |
| (g/100g body weight) | 2.50 ± 0.15 | 2.65 ± 0.26 | 2.79 ± 0.18 |
| Females | |||
| No. of offspring examined | 24 | 20 | 22 |
| Body weight (g) | 17.4 ± 0.7 | 15.7 ± 1.5 | 15.1 ± 0.7 |
| Brain weight (g) | 0.44 ± 0.01 | 0.43 ± 0.01 | 0.43 ± 0.02 |
| (g/100g body weight) | 2.58 ± 0.19 | 2.82 ± 0.24 | 2.90 ± 0.13 |
| PND 77 | |||
| Males | |||
| No. of offspring examined | 32 | 23 | 39 |
| Body weight (g) | 53.0 ± 2.8 | 53.0 ± 4.7 | 48.3 ± 2.1 |
| No. of offspring examined | 20 | 13 | 28 |
| Brain weight (g) | 0.50 ± 0.01 | 0.50 ± 0.02 | 0.50 ± 0.02 |
| (g/100g body weight) | 0.98 ± 0.08 | 0.94 ± 0.10 | 1.04 ± 0.08 |
| Females | |||
| No. of offspring examined | 28 | 27 | 16 |
| Body weight (g) | 42.5 ± 4.4 | 43.7 ± 2.7 | 40.5 ± 3.4 |
| Brain weight (g) | 0.51 ± 0.02 | 0.49 ± 0.02 | 0.48 ± 0.03 |
| (g/100g body weight) | 1.85 ± 0.08 | 1.89 ± 0.09 | 1.95 ± 0.17 |
Abbreviations: PND, postnatal day; AlCl3, aluminum chloride.
Data are expressed as the mean ± SD.
p < .05,
p < .01, compared with the 0-ppm controls by Dunnett’s test or Aspin-Welch’s t-test with Bonferroni correction.
Figure 2.Distribution of immunoreactive cells for (A) glial fibrillary acidic protein (GFAP), (B) SRY (sex determining region Y)-box2 (SOX2), and (C) T box brain protein 2 (TBR2) in the subgranular zone (SGZ), (D) doublecortin (DCX) in the SGZ and granule cell layer (GCL), and (E) neuron-specific nuclear protein (NeuN) in the GCL of male offspring at postnatal day (PND) 21 and PND 77 after maternal exposure to aluminum chloride (AlCL3) from gestational day (GD) 6 to PND 21. Representative images from the 0-ppm controls (left), and the 900-ppm (middle), and 1800-ppm (right) AlCL3 groups at PND 21. Magnification ×400; bar 50 μm. Graphs show the numbers of immunoreactive cells in the SGZ and/or GCL. N = 9–12/group (PND 21: 0-ppm controls, 10; 900-ppm AlCL3, 10; 1800-ppm AlCL3, 10; PND 77: 0-ppm controls, 12; 900-ppm AlCL3, 9; 1800-ppm AlCL3, 11). *p < .05, compared with the 0-ppm controls by Dunnett’s test or Aspin-Welch’s t-test with Bonferroni correction.
Figure 3.Distribution of interneurons immunoreactive for (A) Reelin or (B) parvalbumin (PVALB), and (C) NeuN-immunoreactive postmitotic neurons in the hilus of the hippocampal dentate gyrus of male offspring at PND 21 and PND 77 after maternal exposure to aluminum chloride (AlCL3) from GD 6 to PND 21. Representative images from the 0-ppm controls (left) and the 900-ppm (middle) and 1800-ppm (right) AlCL3 groups at PND 21. Magnification ×400; bar 50 μm. Graphs show the numbers of immunoreactive interneurons in the hilus. N = 9–12/group (PND 21: 0-ppm controls, 10; 900-ppm AlCL3, 10; 1800-ppm AlCL3, 10; PND 77: 0-ppm controls, 12; 900-ppm AlCL3, 9; 1800-ppm AlCL3, 11). *p < .05, **p < .01, compared with the 0-ppm controls by Dunnett’s test or Aspin-Welch’s t-test with Bonferroni correction.
Figure 4.Distribution of (A) proliferating cell nuclear antigen (PCNA)+ proliferating cells in the SGZ, (B) terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)+ apoptotic cells in the SGZ or the GCL, and (C) p21Cip1/Waf1+ cells in the SGZ of male offspring at PND 21 and PND 77 after maternal exposure to aluminum chloride (AlCL3) from GD 6 to PND 21. Representative images from the 0-ppm controls (left) and the 900-ppm (middle) and 1800-ppm (right) AlCL3 groups at PND 21. Arrowheads indicate immunoreactive or TUNEL+ apoptotic cells. Magnification ×400; bar 50 μm. Graphs show the numbers of immunoreactive cells in the SGZ or GCL. In the graphs of (B), left and right columns at each dose indicate the numbers of TUNEL+ cells in the SGZ and in the GCL, respectively. N = 9–12/group (PND 21: 0-ppm controls, 10; 900-ppm AlCL3, 10; 1800-ppm AlCL3, 10; PND 77: 0-ppm controls, 12; 900-ppm AlCL3, 9; 1800-ppm AlCL3, 11). *p < .05, **p < .01, compared with the 0-ppm controls by Dunnett’s test or Aspin-Welch’s t-test with Bonferroni correction.
Figure 5.Distribution of immunoreactive cells for (A) FBJ osteosarcoma oncogene (FOS), (B) activity-regulated cytoskeleton-associated protein (ARC), and (C) cyclooxygenase-2 (COX-2) in the GCL of the hippocampal dentate gyrus of male offspring at PND 21 and PND 77 after maternal exposure to aluminum chloride (AlCL3) from GD 6 to PND 21. Representative images from the 0-ppm controls (left) and the 900-ppm (middle) and 1800-ppm (right) AlCL3 groups at PND 21. Magnification ×400; bar 50 μm. Graphs show the numbers of immunoreactive cells in the GCL. N = 9–12/group (PND 21: 0-ppm controls, 10; 900-ppm AlCL3, 10; 1800-ppm AlCL3, 10; PND 77: 0-ppm controls, 12; 900-ppm AlCL3, 9; 1800-ppm AlCL3, 11). **p < .01, compared with the 0-ppm controls by Dunnett’s test or Aspin-Welch’s t-test with Bonferroni correction.
Figure 6.Distribution of Morin+ cells in the SGZ/GCL of the hippocampal dentate gyrus of male offspring at PND 21 and PND 77 after maternal exposure to aluminum chloride (AlCL3) from GD 6 to PND 21. Representative images from the 0-ppm controls (left) and the 900-ppm (middle) and 1800-ppm (right) AlCL3 groups at PND 21. Magnification ×400; bar 50 μm. Graphs show the numbers of Morin+ cells in the GCL. N = 5/group. *p < .05, **p < .01, compared with the 0-ppm controls by Dunnett’s test or Aspin-Welch’s t-test with Bonferroni correction.
Real-time RT-PCR Analysis Data in the Hippocampal Dentate Gyrus on PND 21 and PND 77
| 0 ppm AlCl3 (Control) | 1800 ppm AlCl3 | |||
|---|---|---|---|---|
| Relative Transcript Level Normalized to | Relative Transcript Level Normalized to | |||
| No. of animals examined | 6 | 6 | 6 | 6 |
| PND 21 | ||||
| Synaptic plasticity | ||||
| | 1.02 ± 0.23 | 1.04 ± 0.32 | 1.63 ± 0.87 | 1.83 ± 0.80 |
| | 1.02 ± 0.24 | 1.01 ± 0.13 | 0.78 ± 0.15 | 0.89 ± 0.10 |
| | 1.02 ± 0.21 | 1.02 ± 0.24 | 0.98 ± 0.31 | 1.14 ± 0.38 |
| Stem cell regulation | ||||
| | 1.02 ± 0.25 | 1.04 ± 0.32 | 0.78 ± 0.19 | 1.02 ± 0.37 |
| | 1.03 ± 0.28 | 1.07 ± 0.42 | 0.89 ± 0.29 | 1.14 ± 0.43 |
| Cell proliferation | ||||
| | 1.01 ± 0.15 | 1.00 ± 0.06 | 0.71 ± 0.15 | 0.81 ± 0.12 |
| Neurotrophic action | ||||
| | 1.03 ± 0.29 | 1.09 ± 0.52 | 0.98 ± 0.19 | 1.29 ± 0.45 |
| | 1.07 ± 0.42 | 1.08 ± 0.48 | 1.21 ± 0.28 | 1.60 ± 0.60 |
| Cholinergic receptors | ||||
| | 1.03 ± 0.30 | 1.04 ± 0.34 | 1.13 ± 0.39 | 1.29 ± 0.35 |
| | 1.01 ± 0.17 | 1.07 ± 0.43 | 0.66 ± 0.25 | 0.82 ± 0.28 |
| | 1.02 ± 0.20 | 1.02 ± 0.20 | 0.82 ± 0.11 | 0.95 ± 0.13 |
| Glutamate transporters/receptors | ||||
| | 1.05 ± 0.41 | 1.05 ± 0.37 | 0.47 ± 0.22 | 0.58 ± 0.21 |
| | 1.12 ± 0.63 | 1.15 ± 0.76 | 1.94 ± 0.97 | 2.19 ± 0.89 |
| | 1.09 ± 0.53 | 1.10 ± 0.48 | 1.12 ± 0.28 | 1.44 ± 0.47 |
| | 1.10 ± 0.50 | 1.09 ± 0.53 | 1.52 ± 0.59 | 2.00 ± 0.93 |
| | 1.03 ± 0.25 | 1.02 ± 0.22 | 1.37 ± 0.44 | 1.56 ± 0.39 |
| | 1.07 ± 0.41 | 1.07 ± 0.45 | 1.77 ± 0.69 | 2.36 ± 1.13 |
| | 1.02 ± 0.24 | 1.11 ± 0.52 | 0.55 ± 0.14 | 0.70 ± 0.15 |
| Apoptosis | ||||
| | 1.01 ± 0.18 | 1.01 ± 0.11 | 0.78 ± 0.13 | 0.89 ± 0.09 |
| | 1.02 ± 0.20 | 1.00 ± 0.08 | 1.06 ± 0.32 | 1.22 ± 0.30 |
| | 1.01 ± 0.17 | 1.02 ± 0.22 | 1.02 ± 0.23 | 1.16 ± 0.17 |
| | 1.04 ± 0.28 | 1.04 ± 0.31 | 0.97 ± 0.12 | 1.27 ± 0.36 |
| | 1.02 ± 0.18 | 1.01 ± 0.16 | 0.95 ± 0.16 | 1.09 ± 0.14 |
| | 1.02 ± 0.20 | 1.02 ± 0.21 | 1.21 ± 0.28 | 1.38 ± 0.22 |
| PND 77 | ||||
| Synaptic plasticity | ||||
| | 1.02 ± 0.21 | 1.01 ± 0.18 | 0.36 ± 0.14 | 0.45 ± 0.15 |
| | 1.06 ± 0.44 | 1.01 ± 0.18 | 0.79 ± 0.38 | 0.96 ± 0.25 |
| | 1.01 ± 0.12 | 1.02 ± 0.18 | 0.79 ± 0.31 | 0.98 ± 0.18 |
| Stem cell regulation | ||||
| | 1.14 ± 0.54 | 1.33 ± 0.55 | 1.49 ± 0.92 | 1.74 ± 0.80 |
| | 1.02 ± 0.24 | 1.01 ± 0.35 | 0.91 ± 0.35 | 1.14 ± 0.22 |
| Cell proliferation | ||||
| | 1.02 ± 0.20 | 1.01 ± 0.16 | 0.72 ± 0.22 | 0.92 ± 0.15 |
| Neurotrophic action | ||||
| | 1.02 ± 0.26 | 1.00 ± 0.09 | 0.86 ± 0.34 | 1.07 ± 0.17 |
| | 1.05 ± 0.39 | 1.04 ± 0.29 | 0.92 ± 0.26 | 1.17 ± 0.10 |
| Cholinergic transporters/receptors | ||||
| | 1.07 ± 0.48 | 1.04 ± 0.32 | 0.89 ± 0.27 | 1.13 ± 0.17 |
| | 1.13 ± 0.60 | 1.13 ± 0.58 | 1.45 ± 0.71 | 1.75 ± 0.45 |
| | 1.04 ± 0.30 | 1.03 ± 0.30 | 1.10 ± 0.49 | 1.34 ± 0.28 |
| Glutamate receptors | ||||
| | 1.26 ± 0.82 | 1.26 ± 0.87 | 2.37 ± 1.35 | 2.82 ± 0.98 |
| | 1.11 ± 0.62 | 1.06 ± 0.39 | 0.79 ± 0.16 | 1.03 ± 0.10 |
| | 1.07 ± 0.47 | 1.04 ± 0.30 | 1.02 ± 0.28 | 1.31 ± 0.15 |
| | 1.04 ± 0.33 | 1.03 ± 0.26 | 0.81 ± 0.19 | 1.05 ± 0.14 |
| | 1.06 ± 0.44 | 1.01 ± 0.18 | 0.86 ± 0.31 | 1.11 ± 0.14 |
| | 1.08 ± 0.52 | 1.05 ± 0.34 | 1.04 ± 0.29 | 1.33 ± 0.21 |
| | 1.10 ± 0.52 | 1.07 ± 0.44 | 1.60 ± 0.97 | 1.91 ± 0.71 |
| Apoptosis | ||||
| | 1.02 ± 0.25 | 1.00 ± 0.08 | 0.72 ± 0.15 | 0.93 ± 0.08 |
| | 1.05 ± 0.31 | 1.04 ± 0.29 | 0.82 ± 0.45 | 0.99 ± 0.35 |
| | 1.02 ± 0.25 | 1.01 ± 0.19 | 1.12 ± 0.48 | 1.41 ± 0.35 |
| | 1.02 ± 0.24 | 1.01 ± 0.17 | 0.89 ± 0.36 | 1.11 ± 0.22 |
| | 1.04 ± 0.37 | 1.01 ± 0.16 | 1.02 ± 0.45 | 1.27 ± 0.27 |
| | 1.09 ± 0.52 | 1.03 ± 0.27 | 0.94 ± 0.36 | 1.22 ± 0.38 |
Abbreviations: Arc, activity-regulated cytoskeletal-associated protein; Bax, BCL2-associated X protein; Bcl2, B-cell leukemia/lymphoma 2; Bdnf, brain derived neurotrophic factor; Casp2, caspase 2; Casp3, caspase 3; Casp9, caspase 9; Casp12, caspase 12; Chrna4, cholinergic receptor nicotinic alpha polypeptide 4; Chrna7, cholinergic receptor nicotinic alpha polypeptide 7; Chrnb2, cholinergic receptor nicotinic beta polypeptide 2; Fos, FBJ osteosarcoma oncogene; Gapdh, glyceraldehyde-3-phosphate dehydrogenase; Gria1, glutamate receptor, ionotropic, AMPA1 (alpha 1); Gria2, glutamate receptor, ionotropic, AMPA2 (alpha 2); Gria3, glutamate receptor, ionotropic, AMPA3 (alpha 3); Grin2a, glutamate receptor, ionotropic, NMDA2A (epsilon 1); Grin2d, glutamate receptor, ionotropic, NMDA2D (epsilon 4); Hprt, hypoxanthine guanine phosphoribosyl transferase; Kitl, kit ligand; Notch1, notch 1; Ntrk2, neurotrophic tyrosine kinase, receptor, type 2; Pcna, proliferating cell nuclear antigen; Ptgs2, prostaglandin-endoperoxide synthase 2; Slc17a6, solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 6; Slc17a7, solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 7.
Data are expressed as the mean ± SD.
p < .05,
p < .01, compared with the 0-ppm controls by Student’s t-test or Aspin-Welch’s t-test.